Skip to main content
Premium Trial:

Request an Annual Quote

GeneArt Nets Additional $800K in Expanded NCI Contract

NEW YORK (GenomeWeb News) – The National Cancer Institute has extended an existing agreement with synthetic genomics company GeneArt to produce genes for the NCI’s Mammalian Gene Collection, the company said today.
 
GeneArt said that it stands to gain an additional $800,000 from the expanded contract, bringing the total value of the agreement to $2.7 million in 2008.
 
The company said it netted $3.5 million in 2007 from the NCI contract, which was renewed earlier this year.
 
GeneArt said that the genes it has produced to date for the MGC are made of complex repeat motifs, are large, and are primarily rare transcripts. The company said it has recently advanced its synthesis processes and developed new production techniques to in order to produce the complex genes efficiently.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.